7 August 2026
1QFY27 Results Update | Sector: Automobile

Apollo Tyres

Estimate change	⟷
TP change	↑
Rating change	⟷

Bloomberg	APTY IN
Equity Shares (m)	635
M.Cap.(INRb)/(USDb)	282.6 / 3
52-Week Range (INR)	541 / 365
1, 6, 12 Rel. Per (%)	-3/-7/2
12M Avg Val (INR M)	536

Financials & valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	284.7	312.3	333.9
EBITDA	41.4	41.3	49.0
Adj. PAT	17.0	17.4	21.0
EPS (INR)	26.7	27.5	33.0
EPS Growth (%)	36.6	2.7	20.2
BV/Share (INR)	328.4	355.2	387.6
Ratios			
RoE (%)	10.8	10.0	11.1
RoCE (%)	13.8	12.4	13.9
Payout (%)	27.8	21.8	21.2
P/E (x)	16.7	16.2	13.5
P/BV (x)	1.4	1.3	1.1
Div. Yield (%)	1.3	1.3	1.6
FCF Yield (%)	8.2	-0.4	1.9

Shareholding Pattern (%)

As of	Jun-26	Mar-26	Jun-25
Promoter	36.9	36.9	37.0
DII	30.6	29.1	29.1
FII	10.5	12.6	12.5
Others	22.0	21.4	21.5

FII includes depository receipts

CMP: INR445 **TP: INR528 (+19%)** **Buy**

Decent performance despite surge in input costs

Europe restructuring benefits to flow in from FY28

- Apollo Tyres (APTY)'s 1QFY27 earnings came in ahead of our estimates at INR3.3b, driven by higher-than-expected other income. Due to RM cost inflation, consol. EBITDA margins dipped 150bp to 11.7% (in line with est.).
- We factor in a steady 8% revenue CAGR on a consolidated basis over FY25-28E. While margins are likely to be under pressure in FY27, we expect them to revive fully in FY28, led by the normalization of cost pressure and the restructuring benefits in Europe. The stock's valuations at 16.2x/ 13.5x FY27E/FY28E EPS appear attractive, especially when compared to those of peers. **We reiterate our BUY rating on APTY** with a TP of INR528 (valued at 16x FY28E consol. EPS).

Input cost headwinds managed well

- Consolidated revenue grew ~13% YoY to INR73.9b (in line) in 1QFY27, while standalone revenue rose ~16% YoY to INR54.6b (in line).
- Consolidated EBITDA margin dipped ~150bp YoY to 11.7% (est. 11.6%) as EBITDA remained flat YoY at INR8.7b (in line).
- APTY reported an exceptional gain of INR235m as an interim distribution with respect to unsecured short-term inter-corporate deposits, which were already written off in earlier years.
- Additionally, other income was greater than expected at INR583m in 1Q.
- Hence, consol. PAT beat our expectations and grew 12.1% YoY to INR3.3b.

Segmental performance:

- Standalone revenue grew 15.6% YoY to INR54.6b. Standalone EBITDA margins improved 80bp YoY to 12% (in line with our expectations), while PAT grew 29.3% YoY to INR2.9b (ahead of estimates).
- EU revenue (in INR terms) grew 10.3% YoY to INR20.4b and EBIT margin contracted significantly by 190bp to 0.7%.

Highlights from the management commentary

- The company further strengthened its leadership position in the replacement market, with TBR replacement market share exceeding 30% and PCR replacement market share of ~21%.
- Demand momentum remained robust in July, with healthy demand across channels and product categories, providing confidence that the positive trend will continue in 2QFY27.
- In the long term, management remains confident of delivering high-teen EBITDA margins for the Europe business once the ongoing restructuring initiatives are fully completed.
- Based on the prevailing cost environment, management estimates that cumulative price hikes of 15-16% would be required to fully offset cost inflation. So far, price hikes of ~11% have been implemented, indicating that one or two additional rounds of pricing may still be necessary.
- Management reiterated its FY27 capex guidance of around INR30b.

Research analyst - Aniket Mhatre (Aniket.Mhatre@MotilalOswal.com) | **Radha Agarwalla** (Radha.Agarwalla@MotilalOswal.com)
Research analyst - Jeemit Shah (Jeemit.Shah@MotilalOswal.com) | **Uday Nair** (Uday.Nair@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Valuation and view

We factor in a steady 8% revenue CAGR on a consolidated basis over FY25-28E. While margins are likely to be under pressure in FY27E, we expect them to revive fully in FY28E, led by the normalization of cost pressure and the restructuring benefits in Europe. The stock's valuations at 16.2x/13.5x FY27E/FY28E EPS appear attractive, especially when compared to those of peers. **We reiterate our BUY rating on APTY** with a TP of INR528 (valued at 16x FY28E consol. EPS).

Consolidated - Quarterly Earning (INR m)

Y/E March	FY26				FY27E				FY26	FY27		VAR
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	
Net Revenues	**65,608**	**68,311**	**77,431**	**73,357**	**73,978**	**76,960**	**83,104**	**78,304**	**284,706**	**312,345**	**75,469**	**-2**
YoY Change (%)	3.6	6.1	11.8	14.2	12.8	12.7	7.3	6.7	12.2	19.6	15.0	
EBITDA	**8,677**	**10,207**	**11,859**	**10,688**	**8,680**	**9,634**	**12,281**	**10,751**	**41,432**	**41,346**	**8,777**	**-1**
Margins (%)	13.2	14.9	15.3	14.6	11.7	12.5	14.8	13.7	14.6	13.2	11.6	
YoY Change (%)	-4.6	16.3	25.2	27.6	0.0	-5.6	3.6	0.6	16.0	-0.2	1.1	
Depreciation	3,776	3,834	3,853	3,967	3,907	4,010	4,100	4,132	15,430	16,150	3,910	
Interest	1,006	1,010	1,001	898	915	1,080	1,100	1,253	3,915	4,348	1,050	
Other Income	189	297	496	352	583	210	225	227	1,334	1,246	155	
PBT before EO expense	**4,085**	**5,660**	**7,501**	**6,175**	**4,441**	**4,754**	**7,306**	**5,593**	**23,421**	**22,094**	**3,972**	**12**
Extra-Ord expense	3,702	1,800	271	4,561	-235	0	0	0	10,335	0	0	
PBT	**383**	**3,860**	**7,229**	**1,614**	**4,676**	**4,754**	**7,306**	**5,593**	**13,086**	**22,094**	**3,972**	
Tax Rate (%)	66.5	33.2	34.9	-290.8	25.4	20.6	20.6	17.4	-4.8	21.0	20.6	
MI & Profit/Loss of Asso. Cos.	-1	-1	-2	-3	-1	-1	-1	3	0	0	-1	
Reported PAT	**129**	**2,580**	**4,705**	**6,310**	**3,489**	**3,775**	**5,802**	**4,618**	**13,718**	**17,448**	**3,155**	
Adj PAT	**2,961**	**4,103**	**5,437**	**4,476**	**3,318**	**3,775**	**5,802**	**4,618**	**16,978**	**17,448**	**3,155**	**5**
YoY Change (%)	-10.6	36.2	59.8	65.3	12.1	-8.0	6.7	3.2	36.5	2.8	6.5	
Margins (%)	4.5	6.0	7.0	6.1	4.5	4.9	7.0	5.9	6.0	5.6	4.2	

E: MOFSL Estimates

Standalone (India)

Net Revenues	**47,254**	**47,149**	**51,390**	**52,370**	**54,619**	**54,221**	**55,244**	**54,949**	**198,162**	**219,034**	**54,342**	**1**
YoY Change (%)	2.9	5.7	13.2	14.3	15.6	15.0	7.5	4.9	9.0	10.5	15.0	
EBITDA	**6,447**	**7,206**	**7,466**	**7,640**	**6,549**	**6,778**	**7,182**	**7,312**	**28,759**	**27,820**	**6,521**	**0**
Margins (%)	13.6	15.3	14.5	14.6	12.0	12.5	13.0	13.3	14.5	12.7	12.0	
Adj PAT	**2,233**	**2,795**	**4,668**	**3,197**	**2,888**	**2,758**	**2,896**	**2,960**	**18,845**	**11,410**	**2,641**	**9**
YoY Change (%)	-1.4	66.9	273.1	122.3	29.3	-1.3	-38.0	-7.4	183.1	-39.5	18.3	

Europe (EUR m)

Net Revenues	**146**	**177**	**180**	**170**	**147**	**177**	**184**	**173**	**678**	**680**	**149**	**-1**
YoY Change (%)	0.0	3.5	-1.6	-3.4	0.7	0.0	2.0	1.5	1.0	0.6	2.0	
Margins (%)	10.8	12.7	17.9	14.6	8.9	11.2	18.4	12.1	14.0	12.9	9.0	

Source: MOFSL Estimates



Highlights from the management commentary

Update on India business

- The India business delivered its highest quarterly revenue to date, driven by broad-based demand across end markets and product categories. The company continued to outperform the domestic tyre industry, recording double-digit growth across almost all product segments and gaining market share in key categories. Strong brand equity, coupled with enhanced consumer visibility through the company's BCCI sponsorship, contributed meaningfully to higher customer traction and incremental volumes.
- Volumes grew across all major channels, with replacement volumes growing by 13%, OEM volumes up 10%, and exports rising by 15% during the quarter.

- Excluding the TBB product category, every major product segment registered double-digit volume growth, highlighting the strength of the underlying demand environment.
- Sales of passenger vehicle tyres witnessed a significant improvement, supported by GST-related demand stimulus and higher brand visibility from the cricket sponsorship campaign.
- The company further strengthened its leadership position in the replacement market, with Truck & Bus Radial (TBR) replacement market share exceeding 30% and Passenger Vehicle replacement market share of ~21%.
- Approximately 12% of the revenue growth during the quarter was volume-led, while the balance was driven by pricing. Management indicated that the full benefit of price increases taken with OEMs will be reflected from 2QFY27 onwards.
- Advertising and sales promotion expenditure reduced by nearly 50% during the quarter following the completion of major marketing campaigns.
- Export performance remained healthy despite mixed regional trends. Europe continued to be the primary export market during the quarter, while exports to West Asia were adversely impacted by geopolitical disruptions. Demand from the US remained subdued as elevated inflation slowed dealer inventory liquidation, leading to slower sales to the US.
- Demand momentum remained robust in July, with healthy demand across channels and product categories, providing confidence that the positive trend will continue in 2QFY27.
- In response to rising input costs, the company implemented a 1-2% price increase in July and announced another ~2% increase in August. While the initial hikes will benefit 2Q, the complete pricing impact is expected to be realized during 2HFY27. The broader industry has also implemented similar price revisions. The company has also undertaken several cost optimization operations to offset RM cost inflation.

Europe business updates

- The Europe business recorded low-single-digit volume growth YoY during the quarter. The Passenger Car Radial (PCR) replacement business continued to outperform the market, delivering double-digit growth, significantly ahead of industry trends. Management expects this positive momentum to continue over the coming quarters.
- Revenue growth in Europe was partially impacted by strategic business transitions, including the migration of agricultural tyre production and the transfer of TBR manufacturing from Hungary to India.
- Sequential decline in agricultural tyre volumes was primarily attributable to the ongoing transition, with volumes declining by high-teens. Around 25% of the agricultural tyre business is currently fulfilled through off-take partnerships.
- Given the limited expansion potential at the Kalamassery facility, the company has adopted an off-take/outsourcing model for premium agricultural tyres rather than investing in a new dedicated manufacturing plant. The Enschede facility had ~20 metric tons per day of capacity in this segment, and setting up a new facility with similar capacity would not be economically viable.

- The closure of the Enschede manufacturing facility at the end of Jun'26 resulted in a temporary overlap of fixed costs and some revenue disruption during the quarter. These transitional costs are expected to normalize over time.
- Management indicated that, excluding the temporary overlap costs associated with the Enschede closure, the Europe business would have delivered EBITDA margins of ~11% during the quarter. The financial benefits from the Netherlands plant closure are expected to begin accruing from 2HFY27, improving both cost efficiency and profitability.
- The Enschede facility previously produced ~750,000 tyres annually, with a substantial portion of this production being transferred to the Hungary facility.
- Production of 14-15-inch passenger car tyres is also being shifted from Hungary to India. This transition began in Sep'25 and is expected to be fully completed by Sep-Oct'26.
- Post the ongoing capacity expansion, passenger car tyre capacity at the Hungary plant is expected to increase from approximately 17,000 tyres per day to around 21,000 tyres per day.
- Management expects recently introduced anti-dumping measures on China imports to support the European business over the medium term.
- Over the longer term, management remains confident of delivering high-teen EBITDA margins for the Europe business once the ongoing restructuring and capacity optimization initiatives are fully completed.
- Reifen financials: Revenue of EUR43m, EBITDA margin of around 3%.

Raw material updates and margin outlook

- Raw material costs in India increased by ~17% YoY in 1QFY27, while management expects a further ~8% QoQ increase in input costs in 2QFY27.
- In 1Q, the company implemented cumulative price increases of ~7-9%. After additional hikes announced in 2QFY27, the total hikes now stood at ~9% for TBR tyres and 11% across other product categories.
- Based on the prevailing cost environment, management estimates that cumulative price increases of ~15-16% would be required to fully offset cost inflation. Approximately 7-8% of the overall cost increase was attributable to INR depreciation. So far, price hikes of ~11% have been implemented, indicating that one or two additional rounds of pricing may still be necessary.
- Average raw material prices in India during the quarter were ~INR225/kg for natural rubber, INR250/kg for synthetic rubber, INR125/kg for carbon black, and INR160/kg for steel cord.
- Management expects domestic rubber prices to gradually correct over the coming quarters, which could provide meaningful cost relief for the industry.
- Cost inflation in Europe was relatively lower than India, with raw material costs increasing by ~8% during the quarter. However, the full impact will be reflected only in 2QFY27.
- To fully offset European cost inflation, management estimates that cumulative price increases of approximately 10% would be required, although only around 3% has been implemented so far.

Update on capex and debt


- Consolidated net debt stood at ~INR17b as of 1Q end, with consolidated net debt-to-EBITDA ratio remaining stable at around 0.4x.
- Management reiterated its FY27 capex guidance of around INR30b, reflecting continued investments in capacity expansion and manufacturing optimization.
- Consolidated capex during 1QFY27 amounted to ~INR6.5b, of which nearly INR5b was invested in the India business.
- Capex is expected to accelerate over the remaining quarters of FY27 as several expansion projects enter execution.
- Management indicated that leverage is expected to increase moderately during the remainder of FY27 as capex spending intensifies, although the balance sheet is expected to remain comfortably positioned.
- The company has established manufacturing capacity for Spacemaster tyres at its Baroda facility, received OEM approvals, and expects commercial supplies to commence shortly.

Other highlights

- India manufacturing facilities operated at a healthy 91% capacity utilization in 1Q, reflecting strong domestic demand and efficient production planning.
- European manufacturing operations recorded an even higher 94% capacity utilization, despite ongoing capacity transfers and restructuring activities.
- The company secured multiple new OEM approvals for EV platforms, strengthening its positioning in the fast-growing EV segment and creating opportunities for future business wins.


Key exhibits

Exhibit 1: Consolidated revenue trend




Source: MOFSL, Company

Exhibit 2: Trend in APTY's India revenue




Source: MOFSL, Company

Exhibit 3: Performance trend in APTY's EU operations




Source: MOFSL, Company

Exhibit 4: Consolidated PAT and PAT growth trends




Source: MOFSL, Company

Exhibit 5: Trend in India's gross margin (%)



Source: MOFSL, Company

Exhibit 6: Trend in the EU's (derived) gross margin (%)



Source: MOFSL, Company

Valuation and view


- **Indian business well-placed for growth over the long term:** The GST rate cut has helped revive demand across segments, with positive demand continuing post the festive season in some of the key segments. With its strong competitive positioning and ready capacities, APTY is well placed to benefit from this trend. Beyond a pickup in domestic demand, exports will continue to be a key growth driver for APTY in the coming years. Overall, we have factored in the Indian business to post a steady 9% revenue CAGR over FY26-28E. Given the commodity headwinds, we factor in a 180bp contraction in EBITDA margins in FY27, which we expect to recover gradually in FY28.
- **A focus on premiumization driving better brand positioning and a healthy margin profile:** The company has been focusing on enhancing its product offerings in both India and Europe. Benefiting from its robust R&D capabilities, the company saw notable enhancements in its sales mix, with the PV revenue contribution rising from 18% in FY18 to 22% in FY26, aligning with its premiumization strategy. In Europe, given the premium status of the Vredestein brand, coupled with the establishment of a cutting-edge manufacturing facility in Hungary, the company is well-positioned to enhance its product portfolio by shifting toward the lucrative premium car tyre segment. This is evident from the rising share of its UHP/UUHP mix in Europe to 50% in 4QFY26 from 48% in 4QFY25. With improved competitiveness, APTY has gained market share in the replacement segment and made inroads with OEMs. Further, the shutdown of its Enschede plant will help lift the European business's performance in FY27.
- **Valuation and view**: We factor in a steady 8% revenue CAGR on a consolidated basis over FY25-28E. While margins are likely to be under pressure in FY27, we expect them to revive fully in FY28, led by the normalization of cost pressure and restructuring benefits. The stock's valuations at 16.2x/ 13.5x FY27E/FY28E EPS appear attractive, especially when compared to those of peers. **We reiterate our BUY rating on APTY** with a TP of INR528 (valued at 16x FY28E consol. EPS).

Exhibit 7: Changes to our estimates

(INR M)	FY26E			FY27E		
	Rev	Old	Chg (%)	Rev	Old	Chg (%)
Net Sales	312,345	312,345	0.0	333,877	333,877	0.0
EBITDA	41,346	41,346	0.0	49,045	48,275	1.6
EBITDA (%)	13.2	13.2	0bp	14.7	14.5	20bp
EPS (INR)	27.5	27.0	1.9	33.0	31.8	3.9


Source: Company, MOFSL

Exhibit 8: One-year forward P/E



Source: MOFSL, Company


Exhibit 9: One-year forward P/B



Source: MOFSL, Company


Story in charts

Exhibit 10: Revenue and growth trends




Source: Company, MOFSL

Exhibit 11: EBITDA and EBITDA margin trends




Source: Company, MOFSL

Exhibit 12: Revenue and growth trends for the EU business




Source: Company, MOFSL

Exhibit 13: EBITDA margin trend for APTY's EU business




Source: Company, MOFSL

Exhibit 14: PAT and PAT growth trends




Source: MOFSL, Company

Exhibit 15: Trend in APTY's return profile




Source: MOFSL, Company

Exhibit 16: FCF to turn negative in FY27 with a rise in capex



Source: MOFSL, Company

Exhibit 17: Net debt to rise a bit with increasing capex



Source: MOFSL, Company

Financials and valuations

Consolidated - Income Statement

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	**172,820**	**209,476**	**245,681**	**253,777**	**261,234**	**284,706**	**312,345**	**333,877**
Change (%)	5.7	21.2	17.3	3.3	2.9	9.0	9.7	6.9
Raw Materials	93,945	123,855	146,371	136,631	146,945	155,536	176,087	184,603
Employees Cost	25,134	25,742	26,199	29,640	31,297	35,416	38,067	39,966
Other Expenses	26,917	34,137	39,975	42,519	47,276	52,322	56,845	60,263
Total Expenditure	**145,995**	**183,735**	**212,545**	**208,790**	**225,519**	**243,274**	**271,000**	**284,832**
% of Sales	84.5	87.7	86.5	82.3	86.3	85.4	86.8	85.3
EBITDA	**26,825**	**25,741**	**33,137**	**44,987**	**35,715**	**41,432**	**41,346**	**49,045**
EBITDA Margin (%)	15.5	12.3	13.5	17.7	13.7	14.6	13.2	14.7
growth	38.4	-4.0	28.7	35.8	-20.6	16.0	-0.2	18.6
Depreciation	13,150	13,997	14,191	14,778	14,984	15,430	16,150	17,981
EBIT	**13,675**	**11,744**	**18,945**	**30,209**	**20,732**	**26,002**	**25,196**	**31,065**
EBIT Margin (%)	7.9	5.6	7.7	11.9	7.9	9.1	8.1	9.3
Int. and Finance Charges	4,430	4,444	5,312	5,059	4,466	3,915	4,348	5,521
Other Income	1,294	1,235	411	1,536	881	1,334	1,246	1,171
PBT bef. EO Exp.	**10,539**	**8,535**	**14,044**	**26,685**	**17,146**	**23,421**	**22,094**	**26,714**
EO Items	4,927	59	-226	1,786	1,687	10,335	0	0
PBT after EO Exp.	**5,612**	**8,476**	**14,269**	**24,899**	**15,460**	**13,086**	**22,094**	**26,714**
Total Tax	2,110	2,091	3,813	7,684	4,253	-632	4,646	5,747
Tax Rate (%)	37.6	24.7	26.7	30.9	27.5	-4.8	21.0	21.5
Reported PAT	**3,502**	**6,385**	**10,456**	**17,219**	**11,213**	**13,724**	**17,448**	**20,967**
Adjusted PAT	**6,576**	**6,429**	**10,290**	**18,607**	**12,436**	**16,984**	**17,448**	**20,967**
Change (%)	38.1	-2.2	60.1	80.8	-33.2	36.6	2.7	20.2

Consolidated - Balance Sheet

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	635	635	635	635	635	635	635	635
Total Reserves	113,796	116,886	125,147	138,387	147,022	166,517	180,154	196,676
Net Worth	**114,431**	**117,521**	**125,782**	**139,022**	**147,657**	**167,152**	**180,790**	**197,311**
Total Loans	65,843	61,937	64,205	49,051	44,104	36,752	41,752	44,252
Deferred Tax Liabilities	7,020	9,014	12,590	16,530	17,988	14,553	14,553	14,553
Capital Employed	**187,294**	**188,471**	**202,577**	**204,603**	**209,749**	**218,457**	**237,095**	**256,116**
Gross Block	261,447	281,920	288,938	292,772	298,400	325,365	360,803	396,404
Less: Accum. Deprn.	99,455	108,165	114,697	125,019	136,663	163,269	179,418	197,399
Net Fixed Assets	**161,992**	**173,755**	**174,241**	**167,753**	**161,736**	**162,096**	**181,385**	**199,005**
Goodwill on Consolidation	2,204	2,158	2,288	2,311	2,374	2,774	2,774	2,774
Capital WIP	11,065	6,182	2,526	3,477	4,354	10,768	10,768	10,768
Total Investments	**1,096**	**4,813**	**4,358**	**5,317**	**452**	**622**	**622**	**622**
Curr. Assets, Loans&Adv.	**82,088**	**84,550**	**90,117**	**90,716**	**104,144**	**116,136**	**124,492**	**131,611**
Inventory	33,185	41,554	44,285	42,457	51,312	54,523	59,902	64,031
Account Receivables	13,808	20,513	24,885	26,648	30,621	31,908	35,941	38,419
Cash and Bank Balance	9,713	8,706	8,360	9,116	8,861	10,293	7,352	6,396
Loans and Advances	25,381	13,777	12,587	12,494	13,350	19,413	21,297	22,765
Curr. Liability & Prov.	**71,151**	**82,987**	**70,953**	**64,971**	**63,311**	**73,940**	**82,946**	**88,664**
Account Payables	28,067	35,309	33,956	29,786	28,744	32,243	34,230	36,589
Other Current Liabilities	38,644	44,193	33,505	31,427	30,168	31,456	37,481	40,065
Provisions	4,440	3,484	3,492	3,757	4,399	10,241	11,235	12,009
Net Current Assets	**10,937**	**1,563**	**19,164**	**25,745**	**40,833**	**42,196**	**41,546**	**42,947**
Appl. of Funds	**187,294**	**188,471**	**202,577**	**204,603**	**209,749**	**218,457**	**237,095**	**256,116**

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)								
EPS	**10.4**	**10.1**	**16.2**	**29.3**	**19.6**	**26.7**	**27.5**	**33.0**
growth	*24.3*	*-2.2*	*60.1*	*80.8*	*-33.2*	*36.6*	*2.7*	*20.2*
Cash EPS	38.8	40.1	48.1	65.6	53.9	63.7	66.0	76.5
BV/Share	224.8	230.9	247.1	273.1	290.1	328.4	355.2	387.6
DPS	3.5	3.3	4.3	5.3	5.0	6.0	6.0	7.0
Payout (%)	63.5	32.3	25.8	19.4	28.3	27.8	21.8	21.2
Valuation (x)								
P/E	43.0	44.0	27.5	15.2	22.7	16.7	16.2	13.5
P/BV	2.0	1.9	1.8	1.6	1.5	1.4	1.3	1.1
EV/Sales	2.0	1.6	1.4	1.3	1.2	1.1	1.0	1.0
EV/EBITDA	12.6	13.1	10.2	7.2	8.9	7.5	7.7	6.5
Dividend Yield (%)	0.8	0.7	1.0	1.2	1.1	1.3	1.3	1.6
FCF per share	20.3	5.3	21.6	43.5	17.2	36.4	-1.6	8.4
Return Ratios (%)								
RoE	6.2	5.5	8.5	14.1	8.7	10.8	10.0	11.1
RoCE (pre-tax)	8.6	7.2	10.5	16.8	11.4	13.8	12.4	13.9
RoIC	5.4	5.3	7.8	11.2	7.9	13.9	9.6	10.7
Working Capital Ratios								
Fixed Asset Turnover (x)	0.7	0.7	0.9	0.9	0.9	0.9	0.9	0.8
Asset Turnover (x)	0.9	1.1	1.2	1.2	1.2	1.3	1.3	1.3
Inventory (Days)	70	72	66	61	72	70	70	70
Debtor (Days)	29	36	37	38	43	41	42	42
Creditor (Days)	59	62	50	43	40	41	40	40
Leverage Ratio (x)								
Net Debt/Equity	0.5	0.4	0.4	0.2	0.2	0.2	0.2	0.2

Consolidated - Cash Flow Statement (INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	5,612	8,477	14,272	25,402	15,466	13,092	22,094	26,714
Depreciation	13,150	13,997	14,191	14,778	14,984	15,430	16,150	17,981
Interest & Finance Charges	4,430	4,444	5,312	5,059	4,466	3,915	3,102	4,351
Direct Taxes Paid	-2,035	-1,222	-2,168	-3,843	-3,926	-4,314	-4,646	-5,747
(Inc)/Dec in WC	4,616	-1,829	-7,845	-5,031	-12,662	4,804	-2,290	-2,357
CF from Operations	**25,772**	**23,867**	**23,762**	**36,366**	**18,328**	**32,927**	**34,410**	**40,941**
Others	-1,303	-2,332	-2,396	-1,971	-97	3,747	0	0
CF from Operating incl EO	**24,469**	**21,535**	**21,367**	**34,395**	**18,231**	**36,674**	**34,410**	**40,941**
(Inc)/Dec in FA	-11,563	-18,164	-7,627	-6,739	-7,306	-13,549	-35,438	-35,601
Free Cash Flow	**12,906**	**3,371**	**13,739**	**27,656**	**10,926**	**23,125**	**-1,028**	**5,340**
(Pur)/Sale of Investments	-12,547	5,960	2,512	-716	4,973	-93	0	0
Others	667	482	331	348	310	232	1,246	1,171
CF from Investments	**-23,443**	**-11,722**	**-4,784**	**-7,107**	**-2,022**	**-13,410**	**-34,192**	**-34,430**
Issue of Shares	10,800	0	0	0	0	-1,129	0	0
Inc/(Dec) in Debt	-3,222	-1,875	-7,484	-16,114	-5,218	-8,030	5,000	2,500
Interest Paid	-3,407	-4,022	-4,793	-4,759	-4,171	-3,648	-4,348	-5,521
Dividend Paid	0	-2,223	-2,064	-2,858	-3,811	-5,385	-3,811	-4,446
Others	-2,869	-2,712	-2,587	-2,802	-3,264	-3,641	0	0
CF from Fin. Activity	**1,302**	**-10,832**	**-16,928**	**-26,534**	**-16,464**	**-21,832**	**-3,158**	**-7,467**
Inc/Dec of Cash	**2,327**	**-1,018**	**-346**	**755**	**-255**	**1,432**	**-2,941**	**-956**
Opening Balance	7,387	9,725	8,706	8,361	9,115	8,861	10,293	7,352
Closing Balance	**9,714**	**8,706**	**8,361**	**9,115**	**8,861**	**10,293**	**7,352**	**6,396**

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.